January 5, 2022
The third option?
Way back in the day when it was becoming obvious that Dexcom and Abbot were going to rule the CGM world we speculated about who would be the third option. Our thought was the CGM market was developing along the same path as the BGM market albeit at a much faster pace. Back in the day LifeScan, Roche, Abbott and Bayer effectively controlled 90% of the BGM market with LifeScan and Roche controlling over 65% between them. Effectively everyone else in BGM and there were lots of wannabes were fighting for table scraps.
The CGM market is currently a duopoly . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
